Colin Sandercock
CIK: 0001724870
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Cue Biopharma, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Apr 9, 2026CUE
Cue Biopharma, Inc.
Award(A)DirectStock Option (right to buy)
200K shares- - Dec 3, 2025CUE
Cue Biopharma, Inc.
Award(A)DirectStock Option (right to buy)
70K shares- - Sep 26, 2025CUE
Cue Biopharma, Inc.
Award(A)DirectStock Option (right to buy)
30K shares- - Mar 21, 2025CUE
Cue Biopharma, Inc.
Award(A)DirectStock Option (right to buy)
200K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Apr 9, 2026 | CUE Cue Biopharma, Inc. | Award(A) Stock Option (right to buy) | 200,000 | - | - | Direct |
| Dec 3, 2025 | CUE Cue Biopharma, Inc. | Award(A) Stock Option (right to buy) | 70,000 | - | - | Direct |
| Sep 26, 2025 | CUE Cue Biopharma, Inc. | Award(A) Stock Option (right to buy) | 30,000 | - | - | Direct |
| Mar 21, 2025 | CUE Cue Biopharma, Inc. | Award(A) Stock Option (right to buy) | 200,000 | - | - | Direct |
1-4 of 4 transactions
About Sandercock Colin
Sandercock Colin (SEC CIK 0001724870) files insider reports with the SEC as SVP, GENERAL COUNSEL of Cue Biopharma, Inc. (CUE).
Signal8 holds 3 ownership filings by Sandercock Colin, all Form 4s, filed between Mar 25, 2025 and Apr 10, 2026. Those filings report 4 transactions, from Mar 21, 2025 to Apr 9, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Sandercock Colin's filings is in BOSTON, MA.
Recent filings by Sandercock Colin
Other insiders filing for Cue Biopharma, Inc. (CUE)
- Ray Sumita, Chief Legal Compliance Officer
- Meluzio Michael Vincent, VP, Prin. Accounting Officer
- Lin Shao-Lee, Chief Executive Officer
- Sarraf Pasha, Director
- Garzone Pamela, Director
- Ahlers James M, Chief Financial Officer